TSLA
Tesla
-- 389.220 SMCI
Super Micro Computer
-- 43.930 PLTR
Palantir
-- 76.340 NVDA
NVIDIA
-- 142.440 SOUN
SoundHound AI
-- 15.010 
More Info on PreClinical Study on OBESITY
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semaglutide showed greater benefits in body weight and liver steatosis.
▪️Additive effects in reducing systemic inflammatory biomarkers with the combination therapy.
▪️Clear trend toward improved body composition with VTX3232 + semaglutide therapy.
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semaglutide showed greater benefits in body weight and liver steatosis.
▪️Additive effects in reducing systemic inflammatory biomarkers with the combination therapy.
▪️Clear trend toward improved body composition with VTX3232 + semaglutide therapy.
Negative
▪️Study results are preclinical and based on DIO mouse models, not human trials.
▪️Potential risks associated with translating preclinical findings to human trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
72839823 : Why is stock going down?